As big pharmas including Takeda and Novo Nordisk flee the cell therapy space and smaller biotechs shutter their operations, ...
Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced the first patient has been dosed in the Phase 1/2 study evaluating CRN09682 in patients with metastatic or locally advanced somatostatin ...
The US Patent and Trademark Office has issued a new patent (US Patent No. 12,472,263) on additional and novel formulations of ...
A 23-month-old with a history of Hirschsprung disease was referred for evaluation of a persistent, severe diaper rash ...
LYMPHIR now available nationwideCRANFORD, N.J., Dec. 1, 2025 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology") ...
ZYNLONTA® in combination with glofitamab (COLUMVI®) demonstrated an 89.8% ORR and 77.6% CR across the 49 efficacy-evaluable patients with a minimum of 6 ...
HIV-positive women have multiple safe birth-control options, but drug interactions, viral load and treatment stability still ...
Hepatocellular carcinoma (HCC) is the sixth leading cause of cancer-related mortality worldwide.1 Despite therapeutic ...
Piper Sandler 37th Annual Healthcare Conference December 3, 2025 8:30 AM ESTCompany ParticipantsDavid Amsellem - MD & Senior ...
Vascarta Inc., is pleased to share results from a new study led by researchers at the U.S. Food and Drug Administration's Center for Biologics Evaluation and Research (CBER), with scientists at the ...
BOCA RATON, FL / ACCESS Newswire / November 28, 2025 / Entero Therapeutics, Inc. (NASDAQ:ENTO) (the “Company”) today announced that it will change its name to GridAI Technologies Corp., effective at ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback